Osimertinib Combined With Bevacizumab in Patients With Brain Metastasis Epidermal Growth Factor Receptor (EGFR) Mutation Positive Metastatic Non-Small Cell Lung Cancer

Sponsor
Qingdao Central Hospital
Study ID
NCT05104281
Phase
PHASE3
Status
Unknown

Conditions

  • Carcinoma, Non-Small-Cell Lung

Eligibility Criteria

Sex
ALL
Age
18 Years - 90 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

There is no positive data on osimertinib in the treatment of metastatic EGFR mutation positive non-small-cell lung cancer (NSCLC). The purpose of this study is to study osimertinib combined with bevacizumab in the management of patients with brain metastasis harboring EGFR mutation.

Key Dates

Start date
Jan 1, 2021
Status verified
Mar 2023
Primary completion
Dec 31, 2023
Completion
Dec 31, 2024

Study Design

Enrollment
60 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: study drug
    osimertinib 80 mg, oral daily and bevacizumab 15mg/KG body weight intravenously infusion every 21 days

Primary Outcome Measure

PFS [ Time Frame: 30 months ]

Related Studies